Site search
2855 results for '' found
A Double-Blind, Active-Controlled, Multiple-Ascending Dose, Phase 1b Study of Aerosolized RSP-1502 Delivered Via the PARI LC Plus® Nebulizer in Subjects with Cystic Fibrosis and Chronic Pseudomon
A Double-Blind, Active-Controlled, Multiple-Ascending Dose, Phase 1b Study of Aerosolized RSP-1502 Delivered Via the PARI LC Plus® Nebulizer in Subjects with Cystic Fibrosis and Chronic Pseudomon
/
A multicenter, randomized, double-blind, chronic-dosing, parallel-group, placebo-controlled phase 3 study to evaluate the efficacy and safety of bendralizumab 100mg in patietns with moderate to v
A multicenter, randomized, double-blind, chronic-dosing, parallel-group, placebo-controlled phase 3 study to evaluate the efficacy and safety of bendralizumab 100mg in patietns with moderate to v
/
Randomized,Embedded,Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) (NCT02735707)
Randomized,Embedded,Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) (NCT02735707)
/
A prospective, double-blinded, randomised study comparing 16g automated full-core and side-notch biopsy needles for percutaneous renal biopsies in renal transplant patients (Trial Not Registered)
A prospective, double-blinded, randomised study comparing 16g automated full-core and side-notch biopsy needles for percutaneous renal biopsies in renal transplant patients (Trial Not Registered)
/
A First-In-Human (FIH) Phase 1/2 Study To Assess Safety, Tolerability, And Preliminary Anti-Tumor Activity Of REGN7945, An Anti-CD38 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, In C
A First-In-Human (FIH) Phase 1/2 Study To Assess Safety, Tolerability, And Preliminary Anti-Tumor Activity Of REGN7945, An Anti-CD38 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, In C
/
Reducing the frequency of outpatient review in people with cystic fibrosis on high-efficacy modulator therapy – a non-inferiority, randomised controlled trial (REFORM) (ACTRN12624000696594)
Reducing the frequency of outpatient review in people with cystic fibrosis on high-efficacy modulator therapy – a non-inferiority, randomised controlled trial (REFORM) (ACTRN12624000696594)
/
REDEEM: A randomised controlled trial of VV ECMO to de-sedate, extubate, and mobilise in hypoxic respiratory failure. (NCT05562505)
REDEEM: A randomised controlled trial of VV ECMO to de-sedate, extubate, and mobilise in hypoxic respiratory failure. (NCT05562505)
/
Recovery-focused Community support to Avoid readmissions and improve participation after Stroke (ACTRN12618001468213)
Recovery-focused Community support to Avoid readmissions and improve participation after Stroke (ACTRN12618001468213)
/
A Randomised Clinical Trial of a digital Self-Management package for people with Interstitial Lung Disease (ACTRN12623001133628)
A Randomised Clinical Trial of a digital Self-Management package for people with Interstitial Lung Disease (ACTRN12623001133628)
/